HC Wainwright restated their buy rating on shares of Dermira (NASDAQ:DERM) in a research report report published on Wednesday, May 8th, AnalystRatings.com reports.
“Valuation and risks to price target achievement. We maintain our Buy rating and $7 price target. The STING program currently contributes approximately 53% to our valuation (no contribution from early stage Lilly program currently) and the APRIL program approximately 43%, with the remainder coming from the anti-CD27 program being developed by Merck (MRK; not rated). Our target is based on our clinical net present value (NPV) model. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile.”,” HC Wainwright’s analyst commented.
A number of other analysts have also recently commented on DERM. Zacks Investment Research upgraded Dermira from a hold rating to a buy rating and set a $8.25 price objective for the company in a research report on Thursday, January 10th. Raymond James upgraded Dermira from an underperform rating to a market perform rating and set a $6.71 price objective for the company in a research report on Thursday, January 17th. Finally, BidaskClub cut Dermira from a hold rating to a sell rating in a research report on Friday, January 25th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the stock. Dermira has a consensus rating of Buy and an average target price of $18.30.
Dermira (NASDAQ:DERM) last announced its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($1.49) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.10) by ($0.39). The company had revenue of $2.45 million during the quarter, compared to analyst estimates of $2.63 million. Dermira had a negative net margin of 510.47% and a negative return on equity of 391.86%. On average, equities analysts anticipate that Dermira will post -5.2 EPS for the current fiscal year.
In other Dermira news, insider Eugene A. Bauer sold 35,000 shares of the company’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $15.00, for a total value of $525,000.00. Following the completion of the sale, the insider now directly owns 43,900 shares in the company, valued at approximately $658,500. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 14.80% of the stock is owned by corporate insiders.
Large investors have recently modified their holdings of the business. GYL Financial Synergies LLC purchased a new position in shares of Dermira in the 1st quarter valued at about $288,000. Jane Street Group LLC grew its stake in Dermira by 200.0% during the 1st quarter. Jane Street Group LLC now owns 39,493 shares of the biopharmaceutical company’s stock worth $535,000 after buying an additional 26,328 shares during the last quarter. HighTower Advisors LLC grew its stake in Dermira by 32.0% during the 1st quarter. HighTower Advisors LLC now owns 17,244 shares of the biopharmaceutical company’s stock worth $235,000 after buying an additional 4,181 shares during the last quarter. Opaleye Management Inc. grew its stake in Dermira by 433.3% during the 1st quarter. Opaleye Management Inc. now owns 400,000 shares of the biopharmaceutical company’s stock worth $5,420,000 after buying an additional 325,000 shares during the last quarter. Finally, Macquarie Group Ltd. purchased a new position in Dermira during the 1st quarter worth approximately $2,033,000. Institutional investors own 93.92% of the company’s stock.
Dermira Company Profile
Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.
Read More: What are the most popular ETFs
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.